SCHEMBL10102796

SCHEMBL10102796

OBOc1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.50
TSHR P16473 1/20 0.43
OGG1 O15527 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAOB P27338 2/20 0.40
AOC3 Q16853 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
KDM4E B2RXH2 2/20 0.39
SLC6A4 P31645 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25646088 0.88 ALOX5 (0.47) WDR5TSHRMAOBRXRARXRB
SCHEMBL240715 0.82 WDR5 (0.44) WDR5TSHROGG1LMNAMAPK1
SCHEMBL25646089 0.79 CYP1A2 (0.43) HTTSMN1; SMN2RXRARXRBCYP1A2
SCHEMBL25646094 0.79 ALOX5 (0.50) MAOB
SCHEMBL4621505 0.77 NPC1 (0.51) WDR5TSHRLMNASMN1; SMN2KMT2A
SCHEMBL14664933 0.77 TSHR (0.42) WDR5TSHRLMNAMAPK1HTT
SCHEMBL11955396 0.76 CYP3A4 (0.48) TSHRLMNACYP2C9DRD2DRD4
SCHEMBL16302122 0.75
SCHEMBL31253853 0.75
SCHEMBL16547240 0.74 SLC6A2 (0.39) SLC6A4CYP2D6CYP1A2CYP2C19SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101333226-A Chiral dual ring [4.4.0] diborate and method for preparing same UNIV WUHAN (CN) 2008-12-31 CN claimed
US-12024536-B2 C-terminal HSP90 inhibitors UNIVERSITY OF KANSAS (US) 2024-07-02 US disclosed
US-11985894-B2 Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof DUK SAN NEOLUX CO., LTD. (KR) 2024-05-14 US disclosed
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 US disclosed
US-20240023429-A1 MONOAMINE COMPOUND AND LIGHT EMITTING ELEMENT INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-01-18 US disclosed
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 US disclosed
US-11795155-B2 Compound having naphthobenzofuranyl structure, material for organic electroluminescence device, organic electroluminescence device, and electronic instrument IDEMITSU KOSAN CO., LTD. (JP) 2023-10-24 US disclosed
US-11785847-B2 Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof DUK SAN NEOLUX CO., LTD. (KR) 2023-10-10 US disclosed
US-20230312501-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-10-05 US disclosed
US-20230276707-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD. (KR) 2023-08-31 US disclosed
US-8575357-B2 Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof AICURIS GMBH & CO. KG (DE) 2013-11-05 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-20130045999-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2013-02-21 US disclosed
US-8361959-B2 Spiro-imidazolone derivatives as glucagon receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-01-29 US disclosed
US-20130012434-A1 NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE MERCK SHARP & DOHME CORP. 2013-01-10 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20100331300-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-30 US disclosed
CN-101333226-A Chiral dual ring [4.4.0] diborate and method for preparing same UNIV WUHAN (CN) 2008-12-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11785847-B2 Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof NFE2L2, ESR1, OR51E2 WDR5 2856/4885TSHR 4374/4885OGG1 106/4885
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH WDR5 934/4885TSHR 295/4885OGG1 4042/4885
US-11795155-B2 Compound having naphthobenzofuranyl structure, material for organic electroluminescence device, organic electroluminescence device, and electronic instrument L1CAM, LEF1, ARL1 WDR5 3656/4885TSHR 2275/4885OGG1 1157/4885
US-20130045999-A1 SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF TPMT, AADAC, PAICS WDR5 1878/4885TSHR 3092/4885OGG1 2950/4885
US-20230276707-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF NFE2L2, ESR1, OR51E2 WDR5 2856/4885TSHR 4374/4885OGG1 106/4885
US-20230312501-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE LEF1, RER1, L1CAM WDR5 3184/4885TSHR 2174/4885OGG1 3049/4885
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER CYP1B1, NOTUM, CYP4F11 WDR5 2371/4885TSHR 4308/4885OGG1 447/4885
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT WDR5 2505/4885TSHR 4662/4885OGG1 2193/4885
US-20130012434-A1 NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE GLP1R, GCGR, GIPR WDR5 2871/4885TSHR 44/4885OGG1 4055/4885
US-12024536-B2 C-terminal HSP90 inhibitors HSP90AB2P, HSP90AB1, HSP90B1 WDR5 1900/4885TSHR 3983/4885OGG1 1870/4885
US-11985894-B2 Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof NFE2L2, ESR1, OR51E2 WDR5 3054/4885TSHR 4284/4885OGG1 129/4885
US-20240023429-A1 MONOAMINE COMPOUND AND LIGHT EMITTING ELEMENT INCLUDING THE SAME MAOA, TPH1, MAOB WDR5 2399/4885TSHR 1007/4885OGG1 1817/4885
US-20100331300-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA WDR5 1888/4885TSHR 2931/4885OGG1 2595/4885
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 WDR5 2594/4885TSHR 2863/4885OGG1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.